Hyper Unveils HyperSpace Trackpad Pro: First Premium Haptic Trackpad for Microsoft Windows
14.10.2025 16:15:00 CEST | Business Wire | Press Release
Hyper®, the creator of innovative tech accessories for creators and power users, today announced the Kickstarter launch of its groundbreaking HyperSpace™ Trackpad Pro, the industry’s most advanced trackpad designed specifically for Microsoft® Windows® users. This next-generation trackpad features advanced piezo haptics, full-force sensing technology, and deep personalization experience, transforming how users interact with their productivity and creative apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986927/en/
The world’s most advanced Windows® trackpad. HyperSpace Trackpad Pro delivers precision, contextual haptics, and full-force sensing.
“With approximately 70 percent of desktops and laptops running Windows, users have long-awaited a premium external trackpad that delivers the exceptional precision and haptic experience they need in a trackpad,” said Gabi Iorio, Director of Global Marketing and Sales, Hyper. “With its unparalleled accuracy, customizable responsiveness, and deep software integration, our new HyperSpace Trackpad Pro gives Windows users an unmatched trackpad solution.”
Engineered for Precision and Personalization
The HyperSpace Trackpad Pro delivers unprecedented precision with its blazing-fast 240Hz response rate, eliminating the latency issues that plague traditional trackpads. Every gesture translates instantly to the screen, enabling pixel-perfect accuracy for video editing, design work, and multitasking.
Third-generation piezo haptic technology provides consistent, satisfying click feedback across its entire glass surface. Unlike mechanical switches with dead zones, every millimeter responds with uniform tactile precision. The integrated full-force sensing matrix recognizes pressure variations, enabling deeper interactions and customizable click profiles from soft to firm feedback.
Hydra® Connect software for Microsoft Windows sets the Trackpad Pro apart from other trackpads by enabling users to create deep-click zones, corner shortcuts, and app-specific profiles that automatically switch based on the active application.
Pre-loaded with profiles for popular applications including Adobe®Premiere Pro, Illustrator and Photoshop, Microsoft®Office, and Figma®, the Trackpad Pro works immediately out of the box. The Hydra® Widget provides instant profile switching and workflow visualization.
While purpose-built for Microsoft Windows with full multitouch gesture support, it offers versatile compatibility with macOS® for basic navigation and clicking functionality.
Features
- More Precise
Experience precision and control at any speed, with zero latency, a 240Hz report rate for smooth performance, and full responsiveness across the entire surface. - More Control
Customize click sensitivity and pressure to match your workflow for reliable, consistent feedback and precise work on detailed tasks. - No Palm Interference
The trackpad detects palms, preventing unwanted cursor movement to keep your workflow distraction-free. - Click Anywhere
Consistent, responsive clicks across the entire surface are provided by embedded haptic feedback, delivering a uniform feel without the unevenness of traditional switches. - Most Premium and Customizable Trackpad Experience for Microsoft Windows
Engineered for seamless Windows integration, this trackpad delivers multitouch gestures like pinch-to-zoom and two-finger scrolling, plus fully customizable shortcuts to match the user’s workflow.
Availability and Pricing
The HyperSpace Trackpad Pro (HS2510GL) will be available through Hyper’s Kickstarter campaign starting today with early bird pricing at $90 and an estimated arrival in Q1 2026. Following the campaign conclusion, it will be sold throughout the US, Europe, and other key global regions for $149.99 SRP.
Assets: https://targus.mediavalet.com/portals/HyperSpace-Trackpad-Pro-media-preview
About HYPER
Celebrating 20 years of enabling creators and innovators to Go Beyond, Hyper® specializes in delivering cutting-edge tech and mobile accessories to creative professionals with its award-winning lineup of power, connectivity, mobility, and desktop solutions. Learn more at hypershop.com and follow us on Instagram, TikTok, X, and LinkedIn.
Prices, dates, features, and specifications are subject to change without notice. ©2025 Hyper. Hyper and HyperSpace are trademarks or registered trademarks of Targus International LLC in the US and certain other countries. Hydra is a registered trademark of Peratech Holdco Limited. Adobe Premiere Pro, Illustrator and Photoshop are either registered trademarks or trademarks of Adobe in the United States and/or other countries. Microsoft, Windows, and Microsoft Office are registered trademarks of the Microsoft group of companies. Figma is a registered trademark of Figma, Inc. macOS is a trademark of Apple Inc., registered in the U.S. and other countries and regions. All other trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013986927/en/
Contacts
For more information, contact:
Rachel Neppes - rneppes@targus.com– Head of PR
714-575-7432
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom